2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Gastrointestinal
4
Other hematologic neoplasm
3
Dermatologic
2
Sarcoma
1
Plasma cell
1
Other neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Endocrine
1
CNS
1
Breast
1
Conditions
Myelodysplastic Syndromes
1477
Leukemia, Myeloid, Acute
1238
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
863
Leukemia
745
Precursor Cell Lymphoblastic Leukemia-Lymphoma
703
Myeloproliferative Disorders
629
Leukemia, Myelomonocytic, Chronic
455
Lymphoma, Non-Hodgkin
447
Primary Myelofibrosis
430
Multiple Myeloma
423
Leukemia, Lymphocytic, Chronic, B-Cell
408
Hodgkin Disease
384
Lymphoma
343
Leukemia, Myeloid, Chronic-Phase
335
Blast Crisis
282
Polycythemia Vera
267
Leukemia, Myeloid, Accelerated Phase
263
Lymphoma, Follicular
254
Lymphoma, Mantle-Cell
253
Burkitt Lymphoma
246
Lymphoma, Large B-Cell, Diffuse
244
Lymphoma, B-Cell, Marginal Zone
225
Congenital Abnormalities
215
Lymphoma, Large-Cell, Immunoblastic
201
Myelodysplastic-Myeloproliferative Diseases
199
Thrombocythemia, Essential
196
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
196
Anemia, Refractory, with Excess of Blasts
194
Hematologic Neoplasms
193
Neoplasms, Plasma Cell
184
Interventions
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplastic Processes
×
Myeloid
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA